Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | The CLL12 trial of ibrutinib in early stage CLL

Petra Langerbeins • 15 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Here, Petra Langerbeins, MD, of the University of Cologne, Cologne, Germany, discusses the key outcomes from the CLL12 study (NCT02863718) looking at the use of ibrutinib in early-stage chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Petra Langerbeins

Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy 2:10
Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins • 16 Sep 2016
Why is personalized medicine important for CLL? 1:00
Why is personalized medicine important for CLL?
Petra Langerbeins • 16 Sep 2016
Prognostic markers for CLL – how do they help determine who gets which treatment? 1:14
Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins • 16 Sep 2016
How to explain the ‘watch-and-wait’ period to a CLL patient? 1:02
How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins • 16 Sep 2016

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals